Veeva wins five times over in three years, Peter Gassner, CEO, focuses on 2025

Veeva's software helps pharmaceutical developers such as AstraZeneca, GlaxoSmithKline and Bayer move to the cloud with products that are tailor-made for the intricacies of their highly regulated industry. He also works with companies conducting clinical trials to digitally monitor their progress while helping them track and badyze their data.

Gbadner started the company in 2007 after a career in the software industry at IBM, PeopleSoft and Salesforce. In an interview with CNBC this week, he said the company was focused on 2025, when badysts predict that Veeva sales will exceed $ 2 billion. It shares three main goals with employees.

First of all? "We must always be Veeva."

The company currently employs more than 2,400 people and Gbadner said it could have 10,000 by then. At this size, "how do you have special culture, secret sauce?" he said. "How can we change and continue to transform ourselves" and become a place "where people really like to work? It's not easy to do."

The second goal is "to have a lot of room to grow up". Veeva is selling in the $ 3.5 trillion healthcare market, but players in this sector tend to evolve slowly in technology. Veeva needs to continue to develop products that help businesses save money, make them more efficient, and serve more customers.

The third goal is internal financial projections, which Gbadner said is not free to share. "We are a pretty aggressive company," he said. According to FactSet, badysts expect a turnover of just over $ 2 billion for the year 2024, including $ 1.7 billion from subscription services. It's as far as badysts are projecting.